Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suxiang Chen

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Nucleic Acid Therapeutics|October 7, 2020
Antisense Oligonucleotides as Potential Therapeutics for Type 2 DiabetesSuxiang Chen, Nabayet Sbuh, Rakesh N Veedu
Pharmaceuticals (Basel, Switzerland)|October 18, 2018
Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular ImagingLeila Hassanzadeh, Suxiang Chen, Rakesh N Veedu
Molecules (Basel, Switzerland)|July 15, 2026
Survivin-Targeting Antisense Oligonucleotides in Cancer TherapyBal Hari Poudel, Suxiang Chen, Rakesh N Veedu
ACS Omega|January 1, 2024
Evaluation of Chemically Modified Nucleic Acid Analogues for Splice Switching ApplicationBao T Le, Suxiang Chen, Rakesh N Veedu
Chemical Communications (Cambridge, England)|October 6, 2025
Systematic evaluation of 2'-<i>O</i>-methyl RNA antisense oligonucleotides with limited phosphorothioate linkages for efficient splice switchingSuxiang Chen, Bal Hari Poudel, Rakesh N Veedu
Biomolecules|July 27, 2024
Rational Design of Chimeric Antisense Oligonucleotides on a Mixed PO-PS Backbone for Splice-Switching ApplicationsBao T Le, Suxiang Chen, Rakesh N Veedu
Genes|June 25, 2020
Development of Novel Chemically-Modified Nucleic Acid Molecules for Efficient Inhibition of Human <i>MAPT</i> Gene ExpressionMadhuri Chakravarthy, Suxiang Chen, Tao Wang, et al.
Theranostics|November 1, 2023
Aptamer-engineered (nano)materials for theranostic applicationsNavid Rabiee, Suxiang Chen, Sepideh Ahmadi, et al.
Theranostics|November 8, 2017
Nucleic Acid-Based Theranostics for Tackling Alzheimer's DiseaseMadhuri Chakravarthy, Suxiang Chen, Peter R Dodd, et al.
RSC Advances|April 25, 2024
Inhibition of survivin by 2'-<i>O</i>-methyl phosphorothioate-modified steric-blocking antisense oligonucleotidesYalin Li, Suxiang Chen, Kamal Rahimizadeh, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Nucleic Acid Therapeutics|October 7, 2020
Antisense Oligonucleotides as Potential Therapeutics for Type 2 DiabetesSuxiang Chen, Nabayet Sbuh, Rakesh N Veedu
Pharmaceuticals (Basel, Switzerland)|October 18, 2018
Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular ImagingLeila Hassanzadeh, Suxiang Chen, Rakesh N Veedu
Molecules (Basel, Switzerland)|July 15, 2026
Survivin-Targeting Antisense Oligonucleotides in Cancer TherapyBal Hari Poudel, Suxiang Chen, Rakesh N Veedu
ACS Omega|January 1, 2024
Evaluation of Chemically Modified Nucleic Acid Analogues for Splice Switching ApplicationBao T Le, Suxiang Chen, Rakesh N Veedu
Chemical Communications (Cambridge, England)|October 6, 2025
Systematic evaluation of 2'-<i>O</i>-methyl RNA antisense oligonucleotides with limited phosphorothioate linkages for efficient splice switchingSuxiang Chen, Bal Hari Poudel, Rakesh N Veedu
Biomolecules|July 27, 2024
Rational Design of Chimeric Antisense Oligonucleotides on a Mixed PO-PS Backbone for Splice-Switching ApplicationsBao T Le, Suxiang Chen, Rakesh N Veedu
Genes|June 25, 2020
Development of Novel Chemically-Modified Nucleic Acid Molecules for Efficient Inhibition of Human <i>MAPT</i> Gene ExpressionMadhuri Chakravarthy, Suxiang Chen, Tao Wang, et al.
Theranostics|November 1, 2023
Aptamer-engineered (nano)materials for theranostic applicationsNavid Rabiee, Suxiang Chen, Sepideh Ahmadi, et al.
Theranostics|November 8, 2017
Nucleic Acid-Based Theranostics for Tackling Alzheimer's DiseaseMadhuri Chakravarthy, Suxiang Chen, Peter R Dodd, et al.
RSC Advances|April 25, 2024
Inhibition of survivin by 2'-<i>O</i>-methyl phosphorothioate-modified steric-blocking antisense oligonucleotidesYalin Li, Suxiang Chen, Kamal Rahimizadeh, et al.
Pageof 3